Glucosamine — What Twenty-Seven Years of Watching Patients Take It Has Taught Me — Form & Function with Dr. Ben
← Medical Education
Clinical Depth

Glucosamine:
What Twenty-Seven Years of Watching Patients Take It Has Taught Me

One of the best-selling supplements in the United States. The evidence for its effectiveness is considerably less impressive than its marketing. Here is what the data actually shows.

Glucosamine is a naturally occurring compound involved in cartilage synthesis. The logic behind supplementing with it is intuitive: cartilage breaks down in arthritis, glucosamine is a cartilage building block, therefore supplementing should slow or reverse that breakdown. It is a reasonable hypothesis. The clinical evidence has not been kind to it.

Multiple large, well-designed trials — including the GAIT trial funded by the NIH — have failed to show meaningful benefit for glucosamine over placebo in most patients with osteoarthritis. The subgroup analyses suggesting benefit in severe arthritis have not been consistently reproduced in subsequent studies.

"I do not tell patients to stop taking glucosamine. I tell them to stop expecting it to rebuild their cartilage — because the evidence does not support that — and to hold realistic expectations about what it may or may not do for their symptoms."

Why do so many people feel it helps?

Several reasons, none of which require the supplement to actually be doing what it claims. Arthritis pain fluctuates naturally — people tend to start a new supplement during a flare and attribute the subsequent improvement to the supplement when the flare resolves on its own. Placebo response in pain conditions is real and clinically meaningful, not a dismissal but an acknowledgment of how powerfully expectation shapes pain experience. And the decision to take an active step toward managing a condition can produce genuine psychological benefit that translates into a better reported outcome.

My practical position

If a patient is taking glucosamine, tolerating it well, and feels it is helping, I do not ask them to stop. The safety profile is excellent, the cost is modest, and subjective benefit matters even when the mechanism is unclear. What I do push back on is the belief that it is rebuilding cartilage or slowing structural disease progression — the evidence does not support those claims.

Evidence over ego applies to what we take the same way it applies to what we do in the operating room. The most honest position on glucosamine is this: it is safe, it may relieve symptoms in some people through mechanisms we do not fully understand, and it will not rebuild your cartilage. Start there, and make a decision that reflects your own experience and values rather than the marketing claims on the label.

More myth-busting content on Instagram every week.

@formandfunctionmd →
References
  1. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine. 2006;354(8):795–808. doi:10.1056/NEJMoa052771
  2. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675. doi:10.1136/bmj.c4675
  3. Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis. Arthritis Care & Research. 2014;66(12):1844–1855. doi:10.1002/acr.22376